HUMIRA CLEARED UP 50 PERCENT OF PSORIASIS/PHYSICIAN CHANGED TO SKYRIZI with HUMIRA (ADALIMUMAB).; Revaccination with different COVID-19 vaccine; Interchange of vaccine products; HEAD, EARS, AND FACE HAD NEW BREAK OUTS OF PSORIASIS/LEGS WERE COVERED WITH PSORIASIS with SKYRIZI (RISANKIZUMAB).; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (HEAD, EARS, AND FACE HAD NEW BREAK OUTS OF PSORIASIS/LEGS WERE COVERED WITH PSORIASIS with SKYRIZI (RISANKIZUMAB).), THERAPEUTIC PRODUCT EFFECT INCOMPLETE (HUMIRA CLEARED UP 50 PERCENT OF PSORIASIS/PHYSICIAN CHANGED TO SKYRIZI with HUMIRA (ADALIMUMAB).), COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect products included non-company products ADALIMUMAB (HUMIRA) for Plaque psoriasis, TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination and RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Plaque psoriasis.    Concurrent medical conditions included Plaque psoriasis.   In 2020, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, the patient received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form. On an unknown date, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) at an unspecified dose. In July 2021, the patient experienced PSORIASIS (HEAD, EARS, AND FACE HAD NEW BREAK OUTS OF PSORIASIS/LEGS WERE COVERED WITH PSORIASIS with SKYRIZI (RISANKIZUMAB).). On an unknown date, the patient experienced THERAPEUTIC PRODUCT EFFECT INCOMPLETE (HUMIRA CLEARED UP 50 PERCENT OF PSORIASIS/PHYSICIAN CHANGED TO SKYRIZI with HUMIRA (ADALIMUMAB).), COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). At the time of the report, PSORIASIS (HEAD, EARS, AND FACE HAD NEW BREAK OUTS OF PSORIASIS/LEGS WERE COVERED WITH PSORIASIS with SKYRIZI (RISANKIZUMAB).) was resolving and THERAPEUTIC PRODUCT EFFECT INCOMPLETE (HUMIRA CLEARED UP 50 PERCENT OF PSORIASIS/PHYSICIAN CHANGED TO SKYRIZI with HUMIRA (ADALIMUMAB).), COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       There was no reported medical history.  Concomitant Drugs Not Reported The patient was on Humira for about a year since 2020. Psoriasis had cleared up about 50 percent and her physician was changed her to Skyrizi. Her whole back psoriasis was cleared up. Her head, ears and face had new break outs of psoriasis since Jul 2021. The Skyrizi was working great for her and psoriasis was clearing up well. But her legs were still covered with psoriasis. It was unknown if patient was enrolled in a COVID-19 vaccine trial. On 28 Jan 2021, She had received first dose of COVID-19 vaccine manufactured by Moderna. On 06 Mar 2021, She had received second dose of COVID-19 vaccine manufactured by Pfizer Biontech. No treatment medication was reported. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   Most recent FOLLOW-UP information incorporated above includes: On 23-Sep-2021: Live Follow up received: Humira added as suspect. New event drug effect incomplete was added.